Aromatase inhibitors in the adjuvant therapy of breast cancer;Aromatasehemmer in der adjuvanten therapie des mammakarzinoms

Therapeutische Umschau

Volumn 61, Issue 6, 2004, Pages 359-364

  Baumann, Ch K ^a   Aebi, S ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VOROZOLE;

ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DRUG EFFICACY; ENDOMETRIUM CANCER; ENZYME INHIBITION; FRACTURE; HUMAN; OSTEOPOROSIS; RECURRENCE RISK; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STANDARD; THROMBOEMBOLISM;

EID: 3042578815     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.6.359     Document Type: Review

References (25)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
2. Aebi S, Castiglione-Gertsch M. Adjuvant endocrine therapy for the very young patients. The Breast 2003; 12: 509-15.
3. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326 (13): 852-6.
4. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14 (1): 78-84.
5. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93 (9): 684-90.
6. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93 (6): 456-62.
7. Gnant M, Hausmaninger H, Samonigg H, Mlineritsch B, Taucher S, Luschin-Ebengreuth G, et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a randomized multicenter trial. Breast Cancer Res. Treat 2002; 76 (Suppl 1): 531.
8. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
9. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in post-menopausal women: survival analysis and updated safety results. Eur J Cancer 2003; 39 (12): 1684-9.
10. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359 (9324): 2131-9.
11. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98 (9): 1802-10.
12. Dowsett M, on behalf of the ATAC trialists' Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003; 82 Suppl 1: 7.
13. Howell A, on behalf of the ATAC Trialists' Group. Effect of anastrozole on bone mineral density: 2-year results of the "arimidex" (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003; 82 Suppl 1: 27.
14. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349 (19): 1793-802.
15. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12 (11): 1527-32.
16. Smith I, Dowsett M, on behalf of the IMPACT Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 2003; 82 Suppl 1: 6.
17. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19 (18): 3808-16.
18. Verma S, Rocchi A, Cheung S. Canadian cost-effectiveness analysis of anastrozole versus tamoxifen in early breast cancer. Breast Cancer Res Treat 2003; 82 Suppl 1: 157.
19. Hillner BE. Cost-effectiveness projections of anastrozole vs. tamoxifen as initial adjuvant therapy in ER-positive early breast cancer. Breast Cancer Res Treat 2003; 82 Suppl 1: 156.
20. Phillips K-A, Bernhard J. Adjuvant Breast Cancer Treatment and Cognitive Function: Current Knowledge and Research Directions. J Natl Cancer Inst 2003; 95 (3): 190-7.
21. Shilling V, Jenkins V, Fallowfield L, Howell T. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 2003; 86 (3-5): 405-12.
22. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003; 21 (13): 2597-9.
23. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21 (17): 3357-65.
24. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Caroti C, et al. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol 2001; 19: 4209-15.
25. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Porpiglia M, et al. Anastrozole appears to be superior to tamoxifen in women already adjuvant receiving tamoxifen treatment. Breast Cancer Res Treat 2003; 82 Suppl, 1: 6.